
Cohance Lifesciences Ltd. share price
NSE: COHANCE · Healthcare
₹457.60 -0.22%
Closing price data, updated 17 Nov 2026. 52-week range: -34.4% from high, +71.6% above low.
Price₹457.60
Market cap₹17,508 Cr
P/E369.6
P/B4.48
ROE4.7%
ROCE4.8%
Debt / equity0.10
Dividend yield0.00%
EPS₹1.24
Book value₹102.25
Operating margin11.2%
Dipscan score33 / 100
Share: WhatsAppX / TwitterTelegram
Cohance Lifesciences Ltd. shareholding pattern
As of Sep 2026: Promoters 57.48%, FIIs 7.71%, DIIs 18.86%, Government 0.00%, Public 7.50%, Others 8.46%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 57.48% | 57.49% | 57.49% | 57.49% | 57.49% | 66.41% |
| FIIs | 7.71% | 6.50% | 5.59% | 6.02% | 6.51% | 7.23% |
| DIIs | 18.86% | 20.09% | 21.79% | 21.57% | 20.82% | 11.40% |
| Government | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 7.50% | 7.71% | 7.04% | 6.76% | 6.42% | 6.40% |
| Others | 8.46% | 8.21% | 8.08% | 8.16% | 8.75% | 8.55% |
| No. of Shareholders | 93,846 | 99,149 | 85,230 | 81,877 | 75,284 | 80,910 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -0.22% | +5.55% | +2.69% | +3.02% | +2.79% | -33.78% |
Growth
| Sales growth, 3 years | +18.3% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | -24.2% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | -14.2% |
| Latest quarter profit vs last year | -79.5% |
Strengths and weaknesses
Weaknesses
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 10.6% over last 3 years.
- Promoters have pledged 94.6% of their holding.
- Debtor days have increased from 88.0 to 110 days.
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Cohance Lifesciences Ltd.?
Cohance Lifesciences Ltd. (COHANCE) last closed at ₹457.60 (-0.22% on the day).
What is the market cap of Cohance Lifesciences Ltd.?
About ₹17,508 Cr.
What is the P/E ratio of Cohance Lifesciences Ltd.?
The price-to-earnings ratio is 369.6, and return on equity is 4.7%.
Figures are calculated from company results and exchange prices and are for information only.